Gina Wentling   Posted in News    Sep 6th, 2018

Earlier Autism Diagnosis Possible for Some Children Based on Metabolic Biomarkers in Blood, New Research Shows

A paper by NeuroPointDX scientists, along with our collaborator Dr. David Amaral (University of California – Davis MIND Institute), published in Biological Psychiatry, is the first publication resulting from the Children’s Autism Metabolome Project (CAMP), the largest study of the metabolism of children with autism spectrum disorder.

Thomas Frazier, Chief Scientific Officer of Autism Speaks, said, “The metabolomics approach in this paper reflects a rational approach not only to detection but also to developing targeted treatments.”

NeuroPointDX is a division of Stemina Biomarker Discovery.

Read the press release.
Read the publication.